Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Sanofi-Aventis will work with Ascenta Therapeutics to develop orally active small-molecule drug candidates that block a protein-protein interaction that suppresses tumor-cell death. Ascenta could receive up to $398 million if compounds blocking the interaction between the proteins HDM2 and p53 reach the market. In a separate deal, Sanofi’s vaccines division will work with French biotech Vivalis to develop fully human monoclonal antibodies against a range of infectious disease targets. Vivalis gets $3.6 million up front, research funding, and up to $42 million for each infectious disease target pursued.
This article has been sent to the following recipient: